'Generic to genetic' transition in cardiovascular and neuropsychiatric drugs: opportunity for personalized medicine.
作者信息
Duconge Jorge, Ruaño Gualberto
出版信息
Pharmacogenomics. 2012 Jul;13(10):1097-100. doi: 10.2217/pgs.12.75.
Abstract
摘要
相似文献
1
'Generic to genetic' transition in cardiovascular and neuropsychiatric drugs: opportunity for personalized medicine.心血管和神经精神药物从通用型到基因型的转变：个性化医疗的机遇
Pharmacogenomics. 2012 Jul;13(10):1097-100. doi: 10.2217/pgs.12.75.
2
Pharmacogenetics and outcome with antipsychotic drugs.药物遗传学与抗精神病药物的疗效
Dialogues Clin Neurosci. 2014 Dec;16(4):555-66. doi: 10.31887/DCNS.2014.16.4/jpouget.
3
Cardiovascular drugs and the genetic response.心血管药物与基因反应。
Methodist Debakey Cardiovasc J. 2014 Jan-Mar;10(1):13-7. doi: 10.14797/mdcj-10-1-13.
4
Personalized Approaches to Cardiovascular Disease: Insights into FDA-Approved Interventions and Clinical Pharmacogenetics.个性化心血管疾病治疗方法：FDA 批准的干预措施和临床药物基因组学的见解。
Curr Pharm Des. 2024;30(21):1667-1680. doi: 10.2174/0113816128309440240427102903.
5
Cardiovascular pharmacogenetics: a promise for genomically-guided therapy and personalized medicine.心血管药物遗传学：基因组引导治疗和个性化医疗的前景。
Clin Genet. 2017 Mar;91(3):355-370. doi: 10.1111/cge.12881. Epub 2016 Nov 30.
6
Pharmacogenetics of cardiovascular drugs.心血管药物的药物遗传学
Curr Opin Cardiol. 2023 May 1;38(3):207-214. doi: 10.1097/HCO.0000000000001038. Epub 2023 Mar 28.
7
Pharmacogenetics in the Treatment of Cardiovascular Diseases and Its Current Progress Regarding Implementation in the Clinical Routine.心血管疾病治疗中的药物遗传学及其在临床常规中的实施现状。
Genes (Basel). 2019 Apr 1;10(4):261. doi: 10.3390/genes10040261.
8
Pharmacogenetics in Cardiovascular Medicine.心血管医学中的药物遗传学
Adv Pharmacol. 2018;83:333-360. doi: 10.1016/bs.apha.2018.04.002.
9
Personalised medicine: not just in our genes.个体化医学：不仅仅与基因有关。
BMJ. 2012 Apr 3;344:e2161. doi: 10.1136/bmj.e2161.
10
Personalized medicine: hope or hype?个性化医疗：希望还是炒作？
Eur Heart J. 2012 Jul;33(13):1564-70. doi: 10.1093/eurheartj/ehs112. Epub 2012 Jun 1.
引用本文的文献
1
Development of an Ancestrally Inclusive Preemptive Pharmacogenetic Testing Panel.一个包含祖先信息的前瞻性药物遗传学检测面板的开发。
Clin Transl Sci. 2025 May;18(5):e70230. doi: 10.1111/cts.70230.
2
Exploring perceptions, knowledge, and attitudes regarding pharmacogenetic testing in the medically underserved.探索医疗服务不足人群对药物遗传学检测的认知、知识和态度。
Front Genet. 2023 Jan 13;13:1085994. doi: 10.3389/fgene.2022.1085994. eCollection 2022.
3
Patients with geographic barriers to health care access are prescribed a higher proportion of drugs with pharmacogenetic testing guidelines.有地理医疗障碍的患者被开出了更高比例的带有药物基因检测指南的药物。
Clin Transl Sci. 2021 Sep;14(5):1841-1852. doi: 10.1111/cts.13032. Epub 2021 May 5.
4
Frequencies of Functional Polymorphisms in Three Pharmacokinetic Genes of Clinical Interest within the Admixed Puerto Rican Population.波多黎各混合人群中三个具有临床意义的药代动力学基因的功能多态性频率。
J Pharmacogenomics Pharmacoproteomics. 2013 Mar 27;4(113). doi: 10.4172/2153-0645.1000113.
本文引用的文献
1
Generic atorvastatin and health care costs.通用阿托伐他汀与医疗保健成本。
N Engl J Med. 2012 Jan 19;366(3):201-4. doi: 10.1056/NEJMp1113112. Epub 2011 Dec 7.
2
Mechanisms of statin-induced myalgia assessed by physiogenomic associations.通过生理基因组关联评估他汀类药物引起的肌肉疼痛的机制。
Atherosclerosis. 2011 Oct;218(2):451-6. doi: 10.1016/j.atherosclerosis.2011.07.007. Epub 2011 Jul 20.
3
Validation of candidate genes associated with cardiovascular risk factors in psychiatric patients.验证与精神疾病患者心血管风险因素相关的候选基因。
Prog Neuropsychopharmacol Biol Psychiatry. 2012 Mar 30;36(2):213-9. doi: 10.1016/j.pnpbp.2011.08.001. Epub 2011 Aug 6.
4
Paraoxonase-1 is a major determinant of clopidogrel efficacy.对氧磷酶 1 是氯吡格雷疗效的主要决定因素。
Nat Med. 2011 Jan;17(1):110-6. doi: 10.1038/nm.2281. Epub 2010 Dec 19.
5
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.主要经皮冠状动脉介入治疗（PCI）使用氯吡格雷的患者中，功能降低的 CYP2C19 基因型与不良临床结局风险相关：一项荟萃分析。
JAMA. 2010 Oct 27;304(16):1821-30. doi: 10.1001/jama.2010.1543.
6
ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons.美国心脏病学会基金会/美国心脏协会氯吡格雷临床警报：针对美国食品药品监督管理局“黑框警告”的应对措施：美国心脏病学会基金会临床专家共识文件特别工作组及美国心脏协会报告，得到心血管造影和介入学会以及胸外科医师学会认可。
J Am Coll Cardiol. 2010 Jul 20;56(4):321-41. doi: 10.1016/j.jacc.2010.05.013.
7
Physiogenomic analysis of statin-treated patients: domain-specific counter effects within the ACACB gene on low-density lipoprotein cholesterol?他汀类药物治疗患者的生理基因组分析：ACACB 基因中特定领域的对低密度脂蛋白胆固醇的反作用？
Pharmacogenomics. 2010 Jul;11(7):959-71. doi: 10.2217/pgs.10.58.
8
Real-world clinical effectiveness, regulatory transparency and payer coverage: three ingredients for translating pharmacogenomics into clinical practice.真实世界临床疗效、监管透明度和支付方覆盖：将药物基因组学转化为临床实践的三个要素。
Pharmacogenomics. 2010 May;11(5):657-60. doi: 10.2217/pgs.10.46.
9
Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study).华法林基因分型降低了住院率，这是 MM-WES（美科梅奥华法林有效性研究）的结果。
J Am Coll Cardiol. 2010 Jun 22;55(25):2804-12. doi: 10.1016/j.jacc.2010.03.009. Epub 2010 Apr 8.
10
2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.2009聚焦更新：美国心脏病学会/美国心脏协会ST段抬高型心肌梗死患者管理指南（更新2004年指南和2007年聚焦更新）以及美国心脏病学会/美国心脏协会/心血管造影和介入学会经皮冠状动脉介入治疗指南（更新2005年指南和2007年聚焦更新）：美国心脏病学基金会/美国心脏协会实践指南工作组报告
Circulation. 2009 Dec 1;120(22):2271-306. doi: 10.1161/CIRCULATIONAHA.109.192663. Epub 2009 Nov 18.
Zotero 插件